Axim Biotechnologies Stock Today
AXIM Stock | USD 0 0 50.00% |
Performance2 of 100
| Odds Of DistressOver 83
|
Axim Biotechnologies is selling at 0.003 as of the 3rd of December 2024; that is 50.00 percent increase since the beginning of the trading day. The stock's lowest day price was 0.002. Axim Biotechnologies has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Axim Biotechnologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of June 2024 and ending today, the 3rd of December 2024. Click here to learn more.
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 186.44 M outstanding shares. More on Axim Biotechnologies
Moving together with Axim Pink Sheet
Moving against Axim Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Axim Pink Sheet Highlights
Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Axim Biotechnologies [AXIM] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.64 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Axim Biotechnologies's market, we take the total number of its shares issued and multiply it by Axim Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Axim Biotechnologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 186.44 M outstanding shares.
Axim Biotechnologies currently holds about 65.16 K in cash with (2.49 M) of positive cash flow from operations.
Check Axim Biotechnologies Probability Of Bankruptcy
Ownership AllocationAxim Biotechnologies holds a total of 186.44 Million outstanding shares. Axim Biotechnologies retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Axim Ownership Details
Axim Biotechnologies Risk Profiles
Mean Deviation | 11.2 | |||
Semi Deviation | 12.68 | |||
Standard Deviation | 20.93 | |||
Variance | 438.05 |
Axim Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Axim Biotechnologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
All Next | Launch Module |
Axim Biotechnologies Corporate Management
Joseph MD | Chief Board | Profile | |
Catalina JD | I Biotech | Profile | |
Dr MBA | I Biotech | Profile | |
John II | CEO Pres | Profile | |
Robert Malasek | CFO Sec | Profile | |
Jeffrey Busby | Sr Devel | Profile | |
Alim SeitNebi | I Biotech | Profile |
Other Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.